Starpharma Holdings Rated Speculative Buy/4, Lead Dendrimer Product Stands At Forefront Of Global HIV/AIDS Prevention Strategies, According To Investrend Research Analyst Sharifzadeh In Initial Benchmark Report

NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate)Starpharma Holdings Limited (OTC: SPHRY) (ASX: SPL) has been rated Speculative Buy/4 by Investrend Research analyst Mohammad Sharifzadeh, CFA, PhD., in his initial Benchmark Report on the company.

“Starpharma Holdings Limited is an emerging company operating in an emerging industry. Starpharma’s business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases.”

Sharifzadeh is also lead analyst for Investrends nanotechnology sector research coverage commissioned by Cronus Capital Markets.

The full Starpharma report, including important disclosures and disclaimers, is at http://www.investrendresearch.com. In it the analyst stated:

Starpharma Holdings Limited is an emerging company operating in an emerging industry. Starpharmas business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases.

VivaGelTM is Starpharmas lead dendrimer product. It is a gel-based microbicide with a nanotech active being developed to prevent sexually transmitted infections in women.

VivaGel addresses markets with huge potentials. Starpharmas VivaGel stands at the forefront of the global HIV/AIDS prevention strategies.

VivaGel has received clearance from the U.S. FDA for human clinical trials and the company has already opened the site in the U.S. to recruit volunteers for the clinical trial of VivaGel for prevention of genital herpes.

We agree with Starpharmas management that acquisition of DNT results in valuable synergies including more U.S. presence, extensive IP portfolio, road to commercialization, and a more diversified product base.

Starpharma has a healthy balance sheet. They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises.

During the Fiscal Year 2006 Starpharmas revenue from government sources was a total of A$6,422,066, almost five times the A$1,409,844 government related revenue in Fiscal year 2005.

Starpharmas major expense item is R&D expense which reflects the Companys active strategy of staying as a leading entity in the dendrimer industry.

Starpharmas loss per share decreased from 6.97 Australian Cents in FY05 to 5.69 Australian Cents in FY06.

The full report, including important disclosures and disclaimers, is available at http://www.investrendresearch.com, and at the companys InvestorPower Page at http://www.investrend.com/company/Company.asp?id= 1518&sPathParam=yes&sAlias=sphry.

(Due to the length of this URL, it may be necessary to copy and paste
it into your Internet browser's URL address field. You may also need
to remove an extra space in the URL if one exists.)

Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

Starpharma Holdings is enrolled in Investrend Researchs pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following. Enrollment fees for the Benchmark research platform are $26,800, which is being paid by Cronus Capital Markets, a third party. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage.

Investrend subscribes to the Standards of Practice for Research Providers at http://www.firstresearchconsortium.com, and its research is enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).

Anyone interested in receiving alerts regarding Starpharma Holdings research should email contact@investrend.com with SPHRY in the subject line.

Contacts

Buchan Consulting Group:
Rebecca Wilson Buchan, Media & PR
+61 2 9237 2800
Mob: +61 417 382 391
rwilson@bcg.com.au
www.bdg.com.au
or
Starpharma Holdings Limited:
Dr. Jackie Farley, CEO
+61 3 8532 2704
jackie.fairley@starpharma.com
http://www.starpharma.com
or
Starpharma Holdings Limited:
Ben Rogers, Company Secretary
+61 3 8532 2702
ben.rogers@starpharma.com
http://www.starpharma.com
or
Investrend Research Div.
Investrend Communications, Inc.
R. Hempel, 718-896-5060
contact@investrend.com
http://www.investrendresearch.com

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.